Business Wire

Pulmonary Experts Recommend Zephyr Endobronchial Valve (EBV) from Pulmonx as Only Minimally-Invasive Emphysema Treatment to Be Used Outside Clinical Trials

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx®, a leader in interventional pulmonology, today announced publication of an expert panel recommendation in Respiration which concluded that only the ...
Business Wire

Pulmonx Announces that Priority Health Now Covers the Zephyr Valve, a Less Invasive Treatment Option for Severe Emphysema (COPD)

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation, a leader in therapeutic pulmonary device technologies, announced today that its Zephyr® Valve is now covered by Priority Health® under its ...
Nasdaq

Zephyr® Valve Treatment Provides Long-Term Quality of Life and Lung Function Improvements for Patients with Severe COPD/Emphysema

New Data Presented at ATS 2021 International Conference Shows Positive, Sustained Benefits to Patients Treated with this First Minimally Invasive, Non-drug Treatment Option REDWOOD CITY, Calif., May ...
News Medical

Pulmonx announces FDA approval of Zephyr Endobronchial Valve to treat severe emphysema

Pulmonx ® Corp. announced today that the U.S. Food and Drug Administration (FDA) has approved the Zephyr ® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the ...
News Medical

NICE releases new guidelines for diagnosis and management of COPD

Pulmonx, a leader in interventional pulmonary device technology announced today that the National Institute for Health and Care Excellence (NICE) in the UK has expanded its guidance on the diagnosis ...